LA JOLLA, Calif.--(BUSINESS WIRE)--Stratagene Corporation (NASDAQ:STGN), a developer, manufacturer and marketer of specialized life science research and diagnostic products, announced today that the federal judge overseeing Invitrogen Corporation vs. Stratagene in the United States District Court for the Western District of Texas has awarded Invitrogen $16.2 million in damages plus pre-judgment interest and ruled that Stratagene must pay Invitrogen’s attorney’s fees, in an amount to be determined by the court. On July 25, 2006, the jury determined that Invitrogen’s 4,981,797 patent is valid and that Stratagene infringed that patent by making and selling its competent E. coli cell products. The jury decided to award Invitrogen a 15% royalty rate on sales between the years 1997 and 2004 (for a total of $7.9 million in damages) and found Stratagene to have willfully infringed the patent only between the years 1997 and 2001.
